Pliant Therapeutics Inc
F:9PT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Pliant Therapeutics Inc (9PT) under the Base Case is 2.5677 EUR per share.
Compared with the current market price of 0.6435 EUR, the stock appears
Undervalued by 75% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Pliant Therapeutics Does
Pliant Therapeutics is a biotechnology company that develops drug candidates for fibrotic diseases, where the body makes too much scar tissue in organs such as the lungs. Its main focus has been on medicines that block integrins, proteins that help drive the scarring process. The company is still in the drug-development stage, so it does not sell a commercial medicine yet.
- Headquarters
- United States of America US
- Employees
- 49
- IPO date
- Jun 3, 2020
Continue 9PT Research
Decided on Pliant Therapeutics? Get an email when 9PT reaches the price you’d buy at. Free with an account.
Other Pliant Therapeutics listings
What is the Intrinsic Value of one 9PT stock?
The intrinsic value for
Pliant Therapeutics Inc (9PT) under the Base Case is 2.5677 EUR.
Is 9PT stock undervalued or overvalued?
Compared with the current market price of 0.6435 EUR, the stock appears Undervalued by 75% .